58.3% and 59.6% of subjects in SINUS-24 and SINUS-52, respectively, had comorbid asthma

Changes in NPS, NC and LMK scores in favour of dupilumab were consistent between subjects with CRSwNP with or without comorbid asthma.

Pie chart showing a value of 58.3% for the SINUS-24 study.
Pie chart showing a value of 59.6% for the SINUS-52 study.

Connect With a Rep

Have questions about DUPIXENT®? Get answers from a representative.

Freedom Support Program

Find out what the Freedom Support Program can bring to your patients and how you can help them access it.



DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300229E
Last updated: 06/2023

paab logo